# Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study

> **NCT01469169** · PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 27 (actual)

## Conditions studied

- Hypertension, Pulmonary

## Interventions

- **DRUG:** Iloprost (Ventavis inhaled, BAYQ6256)

## Key facts

- **NCT ID:** NCT01469169
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-19
- **Primary completion:** 2014-12-26
- **Final completion:** 2016-12-14
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2017-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01469169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01469169, "Inhaled Iloprost (Ventavis): Efficacy, Safety, and Pharmacokinetics (PK) Confirmation Study". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01469169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*